Structure Pharma (GPCR) Company Long-Term Loans and Borrowings

Structure Pharma - graphic logo of issuer GPCR

Structure Therapeutics attracts leading biochemists through its advanced R&D platform and agile startup approach, utilizing stock options for talent retention. This price chart confirms the company's momentum, where the indicator stands at 0.00. The business relies on complex expertise in GPCR receptors and patent protection, while production is based on modern laboratories that strictly adhere to international molecule synthesis standards.

GPCR Structure Therapeutics: Company Long-Term Debts in the range 04/28/2023 - 10/28/2026

Structure Pharma - analytical breakdowns and key metrics (GPCR)

- price and consensus price forecast:
Stock Price structuretx.com|GPCR - Price Target Chart
- market capitalization data:
Market Value Structure Therapeutics|GPCR - Total Company Value
- book capitalization data:
Accounting Value per Share Structure Therapeutics|GPCR - Book Capitalization|Market Capitalization to Book Value Ratio structuretx.com|GPCR - Cumulative Company Assets
- debt and liquidity data:
All Debt to Shareholders' Equity Ratio Structure Therapeutics|GPCR - Long-Term Debt to Equity|Short-Term Debt to Equity Ratio Structure Corp|GPCR - Company Aggregate Debts|Debts to Book Value Structure Therapeutics|GPCR - Company Long-Term Liabilities|Amount of Current Liabilities Structure Therapeutics
Fundamental valuation:GPCR - structuretx.com
Manufactured products of Structure Therapeutics

Developing innovative drugs for diabetes and obesity requires significant capital expenditures, making the level of long-term debt a key indicator of the financial stability of Structure Therapeutics (GPCR). This metric aggregates all liabilities with a maturity of more than one year, allowing investors to assess the long-term credit load and the company's ability to finance its expansion into the metabolic disorders market without risking a loss of liquidity.

Competitors of Structure Therapeutics

ascendispharma.com - Company Long-Term Debts|Company Long-Term Debt Madrigal Pharmaceuticals, Inc. (MDGL)|CORT: Company Long-Term Loans and Borrowings|RYTM (Rhythm Pharmaceuticals Inc) - Company Long-Term Debt|Akero Corp (AKRO) - Company Long-Term Liabilities|MTSR (Metsera Inc) - Company Long-Term Debts|Company Long-Term Debts moonlaketx.com (MLTX)|Crinetics (CRNX) - Company Long-Term Liabilities|Company Long-Term Loans and Borrowings NAMS (NewAmsterdam Pharma Company)|Soleno - Company Long-Term Debt|Company Long-Term Liabilities Amicus Corp FOLD|ETNB (89bio, Inc.) - Company Long-Term Debts|agios.com (AGIO) - Long-Term Debt|MDXG - Company Long-Term Liabilities|Rezolute Inc (RZLT) - Amount of Long-Term Liabilities|LXRX (Lexicon Pharma) - Company Long-Term Debts|Company Long-Term Debts MBX Corp|Company Long-Term Debts Altimmune, Inc. (ALT)|Company Long-Term Debt AARD (aardvarktherapeutics.com)|SGMT: Company Long-Term Debt|BioAge Labs - Long-Term Debt|BMEA - Company Long-Term Debt|QNCX - Company Long-Term Debt|Fractyl Health, Inc. - Company Long-Term Debts|VTVT (vTv Therapeutics) - Long-Term Debt Volume|ATPC: Company Long-Term Debt|Long-Term Debt Volume PLUR|Company Long-Term Debt SYBX (Synlogic, Inc.)|Company Long-Term Liabilities LPCN (Lipocine Corporation)|Company Long-Term Debt MTNB|SPRB - Long-Term Debt Volume|Company Long-Term Liabilities Galecto GLTO|CTCX: Amount of Long-Term Liabilities|Company Long-Term Debt Lumos Pharma Corp LUMO|Company Long-Term Loans and Borrowings Organovo Corp|RDUS (Radius Recycling, Inc.) - Company Long-Term Liabilities